Moreno-Traspas Ricardo, Vujic Igor, Sanlorenzo Martina, Ortiz-Urda Susana
Department of Dermatology, University of California San Francisco, Mt. Zion Cancer Research Center, 2340 Sutter Street N461, San Francisco, CA 94115, USA.
The Rudolfstiftung Hospital, Academic Teaching Hospital, Department of Dermatology, Medical University Vienna, Juchgasse 25, 1030 Vienna, Austria.
Melanoma Manag. 2016 Sep;3(3):195-205. doi: 10.2217/mmt-2016-0008. Epub 2016 Aug 16.
Melanoma is one of the leading cancers worldwide, distinguished for its malignancy and low survival rates. Although the poor outcome could improve with an early diagnosis and a good monitoring of the disease, current melanoma biomarkers display several limitations which make them useless. Interestingly, long-noncoding RNAs are secreted into the bloodstream inside exosomes by a wide range of malignant cells, and several of them have been validated as promising circulating molecular signatures of other tumors, but not melanoma. In this review we propose to explore the booming field of long-noncoding RNAs in order to find potential candidates to be tested as novel melanoma biomarkers, with the ultimate goal of improving melanoma detection, diagnosis and prognosis.
黑色素瘤是全球主要癌症之一，以其恶性程度高和生存率低而著称。尽管早期诊断和对疾病的良好监测可能会改善不良预后，但目前的黑色素瘤生物标志物存在一些局限性，使其毫无用处。有趣的是，多种恶性细胞会将长链非编码RNA分泌到外泌体中并释放到血液中，其中一些已被证实是其他肿瘤有前景的循环分子标志物，但黑色素瘤并非如此。在本综述中，我们建议探索长链非编码RNA这一蓬勃发展的领域，以寻找有潜力作为新型黑色素瘤生物标志物进行测试的候选物，最终目标是改善黑色素瘤的检测、诊断和预后。
